Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 1;37(6):536-546.
doi: 10.1097/QCO.0000000000001065. Epub 2024 Sep 27.

The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies

Violet Z Zhu  1   2 , Miles B Horton  3   4 , Gabrielle M Haeusler  1   2   5   6 , Michelle K Yong  1   2   7   8
Affiliations
Review

The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies

Violet Z Zhu et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: Cytomegalovirus (CMV) infection is associated with severe clinical disease and high morbidity in immunocompromised hosts. Letermovir and maribavir, are two recently developed antiviral drugs used in the prevention and treatment of resistant and refractory CMV. Following the publication of landmark randomized trials and increased use, both clinical trial data and real-world experience has reported the development of antiviral drug resistance. The aim of this review was to comprehensively review the published literature on letermovir and maribavir drug resistance and to describe the clinical scenarios in which they may emerge.

Recent findings: For letermovir, the most frequently detected resistance mutations occur in the UL56 gene (C325Y/W/F) and confer total resistance. Maribavir resistance mutations most often occur in the UL97 gene and resistance-associated variants (RAVs) T409M, H411Y, C480F have all been detected. The clinical context in which letermovir and maribavir resistance occurs include high viral loads at initiation, intensified immunosuppression, subtherapeutic drug exposure because of poor adherence, drug interactions, and inadequate central nervous system (CNS) penetration. Emergence of resistance mutations generally occurs within the first 3 months of initiation.

Summary: The detection of letermovir and maribavir resistance mutations highlights an ongoing clinical challenge in the management of CMV.

PubMed Disclaimer

References

    1. Hakki M, Aitken SL, Danziger-Isakov L, et al. American Society for Transplantation and Cellular Therapy Series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther 2021; 27:707–719.
    1. Venton G, Crocchiolo R, Fürst S, et al. Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin Microbiol Infect 2014; 20:160–166.
    1. Stern A, Alonso CD, Garcia-Vidal C, et al. Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. J Antimicrob Chemother 2021; 76:3020–3028.
    1. Yong MK, Shigle TL, Kim YJ, et al. American Society for Transplantation and Cellular Therapy Series: #4 - cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther 2021; 27:957–967.
    1. Hantz S, Garnier-Geoffroy F, Mazeron M-C, et al. French CMV Resistance Survey Study Group. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010; 65:2628–2640.

MeSH terms